FLT3

Richard Maziarz | ASH 2018 | Key results of the phase II RADIUS study

L:

At the 2018 American Society of Hematology meeting, Richard Maziarz from OHSU Knight Cancer Institute, Portland, US, talks about the findings from the phase II Radius trial investigating standard of care (SOC) with or without midostaurin after allogeneic stem cell transplant (SCT) in FLT3-ITD–mutated acute myeloid leukemia (AML). Adding midostaurin to SOC reduced the risk of relapse at 18 months post-allogeneic SCT. 

Download this article:

You can now download this article in Adobe PDF® format.

Download as PDF
Was this article informative? Thank you for your feedback!